In 2014 Israel’s Teva is launching Zecurity (migraine patch), Adasuve (inhalation powder to treat agitation in schizophrenia patients) and DuoResp Spiromax, (an inhaler). The combined peak sales of these products are estimated to be $1 billion. It also has 15 treatments in Phase III trials.
http://www.reuters.com/article/2014/05/20/teva-pharm-ind-products-idUSL6N0O63LC20140520